Abstract: The present invention relates to: a chimeric antigen receptor comprising an antigen-binding site specifically binding to HLA-G, which is an immune checkpoint; immune cells into which the receptor is introduced; and use thereof. The immune cells can effectively remove cancer cells in which an immune checkpoint is expressed, such that even the activation of endogenous immune cells, which had been suppressed by immune checkpoints, can be expected, and thus can be effectively used as an immunotherapeutic method for various cancer diseases related to HLA-G.

Abstract: The present invention relates to a compound of Formula 1, a preparation method thereof, a pharmaceutical composition comprising the same as an active ingredient, and a use thereof. The compound of Formula 1 according to the present invention can exhibit cell necrosis and ferroptosis inhibitory efficacy in various cells such as heart, kidney, nerve, retina, liver, or lung cells, and accordingly, can be usefully used for prevention or treatment of cell necrosis or ferroptosis-related diseases.

Abstract: The present invention relates to a use of a compound of Chemical Formula 1, an isomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof as a ferroptosis inhibitor, and a method of inhibiting ferroptosis using the same. The compound of Chemical Formula 1 according to the present invention may exhibit an effect of inhibiting ferroptosis in various cells such as cardiac, renal, nerve, retinal, hepatic or pulmonary cells, and thus it may be effectively used in preventing or treating a ferroptosis-related disease.

Abstract: A treatment of rejection of a transplant by a recipient of the transplant is disclosed. Methods for prolonging transplant survival in a recipient of the transplant, prolonging survival of the recipient, delaying and/or suppressing delayed graft function in the recipient, and/or reducing the amount of an immunosuppressant administered for transplantation. The methods include providing the transplant with a CHP or a pharmaceutically acceptable salt thereof is disclosed. Also provided is a method for the production of a pharmaceutical composition for the treatment of a transplant allowing modulating transplant survival in a recipient of the transplant.

Abstract: A new use of a cyclo histidine-proline (Cyclo His-Pro, CHP) is disclosed. A composition including cyclo histidine-proline (CHP) as an active ingredient has an excellent protective effect to protect kidney and liver cells from damage and/or toxicity induced by various causes. The composition is useful and effective in protecting kidney and/or liver cells/tissues and in treating a subject with kidney and/or liver diseases and/or damages.

Abstract: Disclosed is a transformer-based voice recognition technology using an improved voice as a conditioning feature. A voice recognition method performed by a voice recognition system may include inputting, to a voice recognition model, clean voice data estimated by a voice improvement model and voice data including noise and performing voice recognition based on the estimated clean voice data and the voice data including the noise by using the voice recognition model. The voice recognition model may be trained to perform the voice recognition robust against noise through a combination of a voice feature of the voice data including the noise and a voice feature of the estimated clean voice data by using the estimated clean voice data as a conditioning feature.

Abstract: An image sensor includes a substrate, a photoelectric conversion region in the substrate with the substrate defining a substrate trench on the photoelectric conversion region, a floating diffusion region adjacent to a side surface of the substrate trench, in the substrate, a gate dielectric film that extends along the side surface and a lower surface of the substrate trench and a transfer gate electrode which includes a lower gate that fills a portion of the substrate trench on the gate dielectric film and has a first width, and an upper gate that has a second width smaller than the first width on the lower gate. The gate dielectric film includes a lower dielectric film interposed between the substrate and the lower gate and has a first thickness, and an upper dielectric film adjacent to the floating diffusion region and has a second thickness greater than the first thickness.

Abstract: The present application relates to a solid oral preparation and a preparation method therefor, the preparation comprising granules, which comprise: as an active ingredient, a carbamate compound of chemical formula 1, or a pharmaceutically acceptable salt, an isomer, solvate or a hydrate thereof; a diluent; and a binder.

Abstract: The present disclosure relates to a hybrid electric vehicle configured to respond to a required torque while reducing exhaust gas emission in a situation where catalyst heating of an engine is not completed, and a driving control method for the hybrid electric vehicle. The driving control method of the hybrid electric vehicle comprises entering catalyst heating control of an engine when there is a request for catalyst heating and a required torque exceeds a first threshold during traveling in a first mode using an electric motor as a driving source, and entering acceleration feeling increase control when the required torque exceeds a second threshold greater than the first threshold, in which the second threshold is set between the first threshold and a third threshold that is a reference for an entry into a second mode using the engine as the driving source.

Abstract: New uses of Cyclo-HisPro (CHP) or a salt thereof for lowering blood pressure are disclosed. More specifically, the present invention relates to a pharmaceutical composition for lowering blood pressure, containing CHP or a salt thereof, and a functional health food composition containing CHP or a salt thereof; a method for lowering blood pressure using CHP or a salt thereof; a use of CHP or a salt thereof in the manufacture of antihypertensive agents; a pharmaceutical composition or a functional health food, for preventing or treating hypertension or complications thereof, containing CHP or a salt thereof; a method for preventing or treating hypertension or complications thereof by using CHP or a salt thereof; and a use of CHP or a salt thereof in the manufacture of a medicament for preventing or treating hypertension or complications thereof.

Abstract: A pouch type battery case configured to accommodate an electrode assembly, in which electrodes and separators are stacked, according to an embodiment of the present invention for achieving the above object includes: a first cup part and a second cup part, which are arranged parallel to a pouch film and formed to be recessed; and a bridge formed between the first cup part and the second cup part and having a constant width and height, wherein the first cup part includes: a first outer wall formed toward an opposite to the bridge; a second outer wall formed toward the bridge; and a first bottom portion configured to connect the first outer wall to the second outer wall, and the second cup part includes: a third outer wall formed toward the bridge; a fourth outer wall formed toward the opposite to the bridge; and a second bottom portion configured to connect the third outer wall to the fourth outer wall, wherein the fourth outer wall has a height greater than that of the first outer wall.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating chronic kidney disease, the composition including graphene quantum dots as an active ingredient. Graphene quantum dots according to the present invention were observed to exhibit the effects of decreasing the expression of fibronectin, collagen 1al, Bax, TGF-?1, Smad2/3, ?-SMA, etc., which are renal fibrosis-related proteins, and increasing the expression of E-cadherin, Smad7, MnSOD, and SOD1, and thereby suppress renal fibrosis. Accordingly, it is expected that the graphene quantum dots according to the present invention will be able to be effectively used in the field of developing agents for treating or alleviating chronic kidney disease caused by renal fibrosis.

Abstract: The bioenvironmental simulation device according to an embodiment of the present invention includes at least one mounting unit on which cells to be measured are placed, a rotational force application unit configured to rotate the mounting unit so as to apply a rotational force to the cells to be measured placed on the mounting unit, and a culture liquid flow device through which a culture liquid flows across the mounting unit, wherein the culture liquid flows by the culture liquid flow device so as to apply a shear force to the cells to be measured.

Abstract: An unsupervised learning-based detection method according to one technical aspect of the present disclosure relates to an unsupervised learning-based detection method using a supervised-learned model, and includes: generating a first plurality of matrix data on the basis of driving data; generating encoding information by encoding the first plurality of matrix data using a convolutional neural network; modeling a time series feature of the encoding information by using a long short-term memory (LSTM) network, so as to derive a correlation between variables according to a time series; re-implementing a second plurality of matrix data through a deconvolution calculation of the correlation between the variables according to the time series; and determining whether the driving data corresponds to a pre-supervised learned driver profile, on the basis of a difference between the first plurality of matrix data and the second plurality of matrix data.

Abstract: Provided is a method for using selective non-catalytic reduction to reduce nitrogen dioxide in exhaust gas generated during an olefin production process. Nitrogen dioxide generated in a catalyst regeneration step of a continuous PDH process can be efficiently removed by the method of the present disclosure. Ultimately, the generation of visible fumes can be prevented through the removal of nitrogen dioxide.

Abstract: A new use of a cyclo histidine-proline (Cyclo His-Pro, CHP) is disclosed. A composition including cyclo histidine-proline (CHP) as an active ingredient has an excellent protective effect to protect kidney and liver cells from damage and/or toxicity induced by various causes. The composition is useful and effective in protecting kidney and/or liver cells/tissues and in treating a subject with kidney and/or liver diseases and/or damages.

Abstract: A new use of a cyclo histidine-proline (Cyclo His-Pro, CHP) is disclosed. A composition including cyclo histidine-proline (CHP) as an active ingredient has an excellent protective effect to protect kidney and liver cells from damage and/or toxicity induced by various causes. The composition is useful and effective in protecting kidney and/or liver cells/tissues and in treating a subject with kidney and/or liver diseases and/or damages.

Abstract: A Cyclo (his-pro) (CHP) is useful for preventing, ameliorating, or treating fibrosis. A pharmaceutical composition containing CHP may be used for preventing or treating fibrosis. A health functional food composition containing CHP may be used for preventing or ameliorating fibrosis. An antifibrotic composition, a method of preventing, ameliorating, or treating fibrosis by using CHP, and/or a use of CHP in the manufacture of the pharmaceutical composition for preventing or treating fibrosis are disclosed.

Abstract: A cyclo(His-Pro)(CHP) is useful for preventing, alleviating or treating peritoneal fibrosis. A pharmaceutical composition for preventing or treating peritoneal fibrosis, a dietary supplement composition for preventing or alleviating peritoneal fibrosis, and a peritoneal dialysis solution, which all contain CHP is disclosed. Also disclosed are a method for preventing or treating peritoneal fibrosis by using CHP, a peritoneal dialysis method using CHP, a use of CHP during the preparation of a pharmaceutical composition for preventing or treating peritoneal fibrosis, and/or a use of CHP in the preparation of a peritoneal dialysis solution.